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Abstract: Functional, tumor-specific CD8+ cytotoxic T lymphocytes drive the adaptive immune
response to cancer. Thus, induction of their activity is the ultimate aim of all immunotherapies.
Success of anti-tumor immunotherapy is precluded by marked immunosuppression in the tumor
microenvironment (TME) leading to CD8+ effector T cell dysfunction. Among the many facets of CD8+
T cell dysfunction that have been recognized—tolerance, anergy, exhaustion, and senescence—CD8+
T cell senescence is incompletely understood. Naïve CD8+ T cells require three essential signals
for activation, differentiation, and survival through T-cell receptor, costimulatory receptors, and
cytokine receptors. Downregulation of costimulatory molecule CD28 is a hallmark of senescent T cells
and increased CD8+CD28− senescent populations with heterogeneous roles have been observed in
multiple solid and hematogenous tumors. T cell senescence can be induced by several factors including
aging, telomere damage, tumor-associated stress, and regulatory T (Treg) cells. Tumor-induced T cell
senescence is yet another mechanism that enables tumor cell resistance to immunotherapy. In this
paper, we provide a comprehensive overview of CD8+CD28− senescent T cell population, their origin,
their function in immunology and pathologic conditions, including TME and their implication for
immunotherapy. Further characterization and investigation into this subset of CD8+ T cells could
improve the efficacy of future anti-tumor immunotherapy.
Keywords: CD8+CD28− T cells; cancer immunology; glioblastoma; immunotherapy; malignant
glioma; cancer
1. Introduction
The conflict between cancer and the immune system has long been established [1].
Immunotherapies are being investigated to augment the anti-tumor effects of the immune system and
promote long-term cancer control [2]. CD8+ cytotoxic T cells (CTLs) are the main players driving the
adaptive immune response against cancer and execute tumor-specific immune responses, rendering
them the primary endpoint to most immunotherapies [3,4]. Establishment of effective antigen-specific
CD8+ T cells enabled preliminary clinical success of cancer vaccines, oncolytic viruses, adoptive cellular
therapy, and checkpoint inhibitors in several cancers including melanoma, lung cancer, renal cell
cancer, Hodgkin’s lymphoma, etc. [5–7]. Unfortunately, despite their promise, the efficacy of these
treatments varies depending on the type and location of the tumor, and has been ineffective in poorly
immunogenic cancers such as glioblastoma (GBM) [7–13].
A variety of T cell deficiencies have been identified in immunosuppressive tumors that contribute
to the ultimate ineffectiveness of CD8+ CTL-mediated tumor killing [14]. Immune tolerance, anergy,
and exhaustion of CD8+ T cells have been studied extensively in the past [14–17]. While the concept
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of immune senescence, defined by terminally differentiated cells in cell cycle arrest after extensive
replication or in response to cellular damage or stress, has been well established with aging and
chronic infections [18–21], our knowledge of its role in cancer is still in its early stages. CD28 is an
indispensable costimulatory molecule needed for the activation of T cells and its role is critical to the
proper activation of CD8+ CTLs [22]. Current evidence shows that the downregulation of CD28 is a
hallmark of senescent CD8+ T cells and CD28− senescent T cells display immunosuppressive functions
in cancer [23–26].
In this review, we will focus on the recent advances in our understanding of CD8+CD28− T cells.
We first will discuss cellular senescence and the evolution of the CD28− T cells. Next, we will review
the significance of CD8+CD28− T cells in multiple disease processes, including transplant, autoimmune
disease, chronic viral infection, and cancer, including CNS tumors. Finally, we will discuss the
functional implications of CD28− T cells in onco-immunology and the important areas of future
investigation on novel immunotherapeutic strategies.
2. Role of CD8+ T Cells in Cancer Immunology
CD8+ T cells are a subset of lymphocytes committed to detecting peptide antigens presented by
major histocompatibility complex (MHC) class I molecules (Figure 1) [27,28]. CD8+ T cells arise from
common lymphoid progenitors that migrate from the bone marrow to the thymus where they pass
through a series of distinct phases of maturation [29,30]. The naïve CD8+ T cell pool is comprised of
polyclonal T cells that express CD28, CCR7, and CD62L, the latter two allowing them to recirculate
between blood and secondary lymphoid organs [31,32]. Initial priming of CD8+ T cells involves T cell
receptor (TCR) recognition of peptide/MHC complexes presented by professional antigen presenting
cells (APCs), such as dendritic cells (DCs). DCs also express surface markers CD70 and CD80/CD86 for
binding to CD27 and CD28 receptors expressed on CD8+T cells. This provides a critical secondary
signal for T cell activation. Host cells, including cancer cells, can serve as targets for previously
activated CD8+ T cells by processing and presenting antigenic tumor peptides by MHC class I.
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Figure  1.  The  priming  and  inactivation  of CD8+  T  cells.  The  interaction  between  TCRs  and  the 
peptide‐MHC complex is the first step toward antigen‐induced CD8+ T cell activation. This creates a 
site  of  extensive  contact  between  T  cells  and  APC,  also  called  immunological  synapses, where 
binding of CD28 on T cells with CD80/CD86 on APCs transduces a pivotal secondary costimulatory 
signal  to  complete  the priming of naïve CD8+ T  cells.  In addition, CD4+ T helper  (Th)  cells when 
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Figure 1. The priming and inactivation of CD8+ T cells. The interaction between TCRs and the
peptide-MHC complex is the first step toward antigen-induced CD8+ T cell activation. This creates a
site of extensive contact between T cells and APC, also called immunological synapses, where binding
of CD28 on T cells with CD80/CD86 on APCs transduces a pivotal secondary costimulatory signal to
complete the priming of naïve CD8+ T cells. In addition, CD4+ T helper (Th) cells when activated
by DCs acquire not only the synapse-composed MHC class II and costimulatory molecules (CD54
and CD80), but also the bystander peptide-MHC-I complex from DC and become CD4+ Th-APCs,
resulting in direct CD4+ T–CD8+ T cell interactions and subsequently delivery of CD40L signaling
to CD40-expressing CD8+ T cells [21]. Furthermore, CD4 Th cells also secrete cytokines, such as IL-2,
which promotes the differentiation of naïve CD8+ T cells into effector CTLs and memory CD8+ T cells.
CTLs destroy antigen-specific target cells (such as cancer cells or viral infected host cells) via pathways
including granule exocytosis, Fas ligand, and TRAIL-mediated apoptosis leading to tumor control
or virus clearance and subsequent physiological T-cell inactivation as well as memory CD8+ T-cell
formation [33]. Whereas pathological T-cell inactivation or conversion of CTL to CD8+ senescent T cells
leads to tumor progression and virus replication.
In addition, CD4+ T helper cells interact with CD8+ T cells and modulate CD8+ T cell activation [34–36].
Activated CD4+ T helper cells can secrete a variety of cytokines, such as interferon-gamma (IFN-γ)
and IL-2, and facilitate CD8+ T cells’ optimal proliferation and activation [28,37]. CD4+ T cells could
also help with DC maturation for expression of costimulatory molecules and secretion of cytokines
that contribute to CD8+ T cell priming [38]. A similar mechanism is also carried out by natural killer
(NK) cells, showing that there is collaboration between CD4+ T cells with NK and DCs for induction of
CD8+ T cell priming [28,38].
Upon activation, effector CD8+ CTLs destroy antigen-expressing cancer cells primarily
utilizing two main pathways: granule exocytosis (such as perforin and granzyme) and death
ligand/receptor-mediated apoptosis (such as Fas ligand and TRAIL) [39]. Additionally, activated CD8+
T cells release IFN-γ and tumor necrosis factor alpha (TNF-α) to induce cytotoxicity in the target
cells and stimulate M1 macrophage-mediated anti-tumor response [28]. In multiple solid tumors,
tumor-infiltrating CD8+ CTLs can be used as a prognostic factor [40–48]. For example, in breast cancer,
significantly increased CD8+ T cells at tumor sites have been shown to have an inverse correlation with
advanced tumor stages and a positive correlation with clinical outcomes [41,49,50]. Similar findings
of a favorable prognosis associated with the accumulation of tumor-infiltrating CD8+ T cells were
reported in colorectal, oral squamous cell, pancreatic, and ovarian carcinomas [43–45,47,48,51].
3. CD28 Costimulatory Receptor
The CD28 costimulatory receptor, a 44-kDa membrane glycoprotein, is expressed on nearly all
human T lymphocytes at birth [52]. Binding of the CD28 receptor on T cells provides an essential second
signal alongside TCR ligation for naïve T cell activation. CD28 signaling has diverse effects on T cell
function, including orchestrating membrane raft trapping at the immunological synapse, transcriptional
changes, downstream post-translational modifications, and actin cytoskeletal remodeling [52–54].
This leads to intracellular biochemical events such as survival and proliferation signals, induction
of IL-2, activation of telomerase, stabilization of mRNA for several cytokines, increased glucose
metabolism, and enhanced T cell migration and homing [52,55,56].
CD28 family of costimulatory molecules also includes ICOS, CTLA-4, PD-1, PD1H, TIGIT, and
BTLA [41]. This family of receptors and ligands has considerable complexity in both binding pattern
and biological effects. For instance, CD28 (activating) and CTLA-4 (inhibitory) are highly homologous
and compete for the same ligands (CD80 and CD86) and regulate immune response by providing
opposing effects [51,52].
The critical role of CD28 in induction of immune response was demonstrated in mice treated
with CD28 antagonist, which induced antigen specific tolerance and prevented the progression of
autoimmune diseases and organ graft rejection [57]. This has led to the development of abatacept
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(Orencia® Bristol-Myers Squibb, New York, NY, USA) [58] and belatacept (Nulojix® Bristol-Myers
Squibb New York, NY, USA) [59], a modified antibody composed of Fc region of IgG1 fused to the
extracellular domain of CTLA-4, which bind to CD80/86 on APCs and block the costimulatory signaling
by CD28. Abatacept and belatacept are used clinically to treat rheumatoid arthritis and organ transplant
rejection, respectively [56,60].
On the other hand, the use CD28 agonists to awaken T cells from the tolerant state could lead
to new therapies to re-activate the immune system for the treatment of infectious disease [61] and
cancer [62]. Although, in a phase I trial of systemic administration of CD28 superagonist monoclonal
antibodies (mAb) (TGN1412), uncontrolled CD28 signaling led to a potent induction of downstream
immune activation independent of TCR-CD3 complex resulting in catastrophic systemic inflammatory
syndromes in six volunteer subjects [63]. Investigation of these unexpected serious adverse events
have led to better design of clinical trials and appreciation of differences in CD28 expression and
regulation between species (critical for transitioning preclinical testing to clinical investigations) [64,65].
An updated CD28 superagonist TAB08 is under clinical testing for rheumatoid arthritis [64]. In addition,
localized or targeted use of anti-CD28 mAbs has much potential such as incorporating the intracellular
costimulatory domain of CD28 into CAR (chimeric antigen receptor) T cells for adoptive transfer
immunotherapy and the use of CD28 agonist aptamer with tumor vaccine [66–68].
Importantly, the use of these therapeutics are in clinical trials for a variety of disease states
including solid neoplasms and inflammatory diseases (Table 1). Although previous experience with
CD28 agonist mAbs has been disappointing, headway is being made in their use in solid tumors
and rheumatoid arthritis. Perhaps out of an abundance of caution, current clinical trials for the use
of CD28 agonists are testing their safety, efficacy, and tolerability in patients and are undergoing
dose escalation studies. Fortunately, significant progress has been made into CAR-T cell therapy
incorporating costimulatory domains and has led to the FDA-approval of the CAR-T cell therapy
tisagenlecleucel (KYMRIAH® Novartis Pharmaceuticals, Basel, Switzerland) for relapse or refractory
acute lymphoblastic leukemia patients [69,70].
Table 1. Clinical trials related to the therapeutic use of CD28 manipulation, such as CAR-T cell therapy
and monoclonal antibodies.
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Furthermore, recent progress in the manipulation of other costimulatory molecule such as
ICOS, CD137 (4-1BB), OX40, and GITR has also demonstrated tremendous therapeutic potential [74].
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Activation of ICOS, CD137, and OX40 via mAbs and aptamers improved T cell proliferation, function,
and overall antitumor response [74–77]. Targeting of GITR exhibited effects on both effector and
regulatory T cells. Ligation of constitutively expressed GITR on regulatory T cells caused depletion
in their number, loss lineage stability and immunosuppressive function [78,79], while GITR agonists
work synergistically with PD-1 blockage to promote CD4 and CD8 accumulation in murine ovarian
cancer [80]. Blockade of inhibitory receptor CTLA-4 have been shown to be effective in enhancing
CD28 signaling and augmenting ICOS stimulation [74,81]. Combination of checkpoint inhibitors and
costimulatory agonists presents an exciting avenue of cancer treatment and several clinical studies are
currently investigating their benefit [74].
4. Cellular Senescence in the Immune System
Cellular senescence is a state of cell cycle arrest in respond to cellular damage or stress
to prevent neoplastic transformation [82]. Cellular senescence have been identified in areas of
physiological homeostasis, such as development [82], wound healing [83], and placental natural killer
lymphocytes [84]. However, cellular senescence also contributes to the loss of function associated
with aging and age-related disease as well as chronic viral infection, neurodegenerative disease,
and cancer [18,85,86]. Two categories of cellular senescence have been described in literature: the
first is aging associated, telomere-dependent replicative senescence and the second is stress-induced
premature senescence, also known as telomere-independent senescence [82,87]. Oncogene-induced
senescence is one of the well-described mechanisms for premature senescence [87,88]. Regardless of
the initiating mechanism, cells that undergo senescence survive by exhibiting a variety of phenotypical
and molecular features (Figure 2), including morphological changes, cell division blockage, change
of sensitivity against apoptosis, metabolic dysfunction, and a specialized secretory activity termed
senescence associated secretory phenotype (SASP) [20]. Additional characteristics include nuclear p16
and p21 expression [89–91], DNA damage [92], senescence associated heterochromatin foci (SAHF) [93],
and increased lysosomal senescence-associated β-galactosidase (SA-β-gal) activity [91]. Recently,
lipofuscin accumulation was also established as a hallmark of senescent cells [94].
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immune  response  declines  with  age  particularly  in  the  elderly  population  [96,97].  Immune 
deficiencies start to appear  in DCs, NK cells, and monocytes/macrophages with aging, and  it was 
Figure 2. Phenotypical and molecular changes in cellular senescence. A variety of intracellular (DNA
damage, oncogenes, etc.) and/or extracellular signals (oxidative stress, chronic inflammation, etc.) can
induce cellular senescence. Senescent cells exhibit numerous characteristics including but not limited
to cell cycle arrest, increased nuclear p16 and p21 expression, increased lysosomal SA-β-gal activity,
shortened telomere, and increased lipofuscin. Senescent cells can also present as a specialized secretory
phenotype termed senescence associated secretory phenotype (SASP). Of particular interest, senescent
immune cells present with lowered expression of CD28 and CD27 but heightened expression of CD57,
KLRG-1, TIGIT, and other NK-cell associated surface receptors.
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Cellular senescence also occurs in the human immune system [18,95]. The effectiveness of the
immune response declines with age particularly in the elderly population [96,97]. Immune deficiencies
start to appear in DCs, NK cells, and monocytes/macrophages with aging, and it was proposed that
myeloid-derived suppressor cells (MDSC) could also induce senescence in T and B cells compartment
in diverse inflammatory conditions [96,97]. Importantly, lymphocytes, especially T cells, show the
most considerable changes with aging [95,98]. Among the various complex features that contribute
to the aging-associated changes in T cell immunity, the accumulation of CD28− T cells is one of the
hallmark phenomena in T cell immunosenescence [26,99,100]. TME can also induce senescence in
tumor-infiltrating T cells [14].
5. Role of CD8+CD28− T Cells
Although CD28 is expressed on the majority of the CD8+ T cells at birth [52], normal aging
process and activation of CD8+ T cells invariably leads to CD28 downregulation [101]. CD8+CD28−
cells represent a distinct population distinguishable from the general population of CD8+CD28+
T cells [99], which are known for their crucial role in the clearance of cancer and intracellularly infected
cells, in terms of their phenotype and function [102]. In vitro studies showed purified CD28+ T cells
progressively lose CD28 during each successful stimulation, with the CD8+ T cells losing their CD28
more rapidly than the CD4+ T cells [26,103,104]. The differential rate of CD28 loss is associated
with the rapid inactivation of telomerase and CD8+ T cells reach replicative senescence faster than
CD4+ T cells, at which stage T cells are no longer able to enter mitosis but still remain viable [105].
Thus, these CD8+CD28− T cells are defined as senescent T cells. Less than 50% of the CD8+ T cell
compartment of elderly or chronically infected individuals are CD28+ while up to 80% of CD4+ T cells
maintain their CD28 expression even in the centenarians [26,103]. Interestingly, a large proportion of
CD8+CD28− T cells of elderly persons also have lower levels of CD8 expression [106,107]. Although
the significance of this observation is unknown, downregulation of the expression of CD8 and CD4
molecules is characteristic for activated T cells, suggesting that those CD8lowCD28− T cells subset
represent senescent lymphocytes that are chronically activated from either common persistent antigens
(in the setting of aging) or persistent infection or inflammation (in the setting of cancer) [25,108].
6. Characteristics of CD8+CD28− Senescent T cells
CD8+CD28− T cells are highly oligoclonal and terminally differentiated effector lymphocytes that
have lost their capacity to undergo cell division [23,108]. They are functionally heterogeneous and
their characteristics vary depending on the context where they are found (Figure 3) [23,108]. They also
express a variety of other NK cell-related receptors including KIR, NKG2D, CD56, CD57, CD94, and Fc-γ
receptor IIIa and have features crossing the border between innate and adaptive immunity [109,110].
Alterations in the costimulatory receptor NKG2D signaling and expression levels in CD8+ T cells can
lead to autoimmune conditions that are either TCR dependent or TCR-independent [111–113]. Gained
expression of CD57, also known as HNK-1 (human natural killer-1), is a common feature associated
with circulating senescent T cells, and increased CD8+CD28−CD57+ senescent T cells were identified in
multiple pathological conditions, including HIV infection, multiple myeloma, lung cancer, and chronic
inflammation conditions such as diabetes and obesity [99,114,115]. Although expression of CD57 is
linked to antigen-induced apoptosis of CD8+ T cells [116], the acquisition of CD94 has been reported
to confer resistance to apoptosis in CD8+CD28− T cells. [117] Similarly, CD8+CD28− T cells are often
associated with the lack of perforin, rendering them ineffective Ag-specific killers in chronic viral
infections [21,118–120]. On the other hand, in certain disease processes such as chronic obstructive
pulmonary disease (COPD) and rheumatoid arthritis, they have been reported to express increased
levels of cytotoxic mediators, perforin and granzyme B, and pro-inflammatory cytokines, IFN-γ and
TNFα, where CD8+CD28− T cells can cause significant damages to normal surrounding tissue in an
antigen-nonspecific manner [121].
Int. J. Mol. Sci. 2019, 20, 2810 7 of 22
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW    7  of  21 
 
 
Figure  3.  The  heterogeneous  functions  of CD8+CD28−  T  cells.  CD8+CD28−  T  cells  originate  from 
activated CD8+CD28+ T cells or from  interaction with tolerogenic APCs. CD8+CD28− T cells exhibit 
both  cytotoxic  and  immunoregulatory phenotypes  and vary  in pathological  states  such  as  across 
different cancer types or inflammatory/autoimmune conditions. 
CD8+CD28− T cells are also shown to be immunosuppressive and function as regulatory T cells 
[122–125].  For  example,  CD8+CD28−  T  cells  directly  inhibit  Ag‐presenting  function  of  DCs  by 
inducing  inhibitory  receptors,  such  as  immunoglobulin  like  transcript  3  (ILT3)  and  ILT4, which 
leads  DCs  to  be  immune  tolerant  than  immunogenic  [122,126].  Such  tolerogenic  DCs  anergize 
alloreactive CD4+CD25+ T cells and convert them into regulatory T cells, which in turn, continue the 
immunosuppressive  cascade  by  tolerizing  other  DCs  and  amplify  T  cell  immunosenescence 
[126,127].  In  vivo,  CD8+CD28−  T  cells  have  been  directly  correlated  with  the  suppression  of 




CD8+CD28‐  T  cells  play  a  significant  role  in  pathological  conditions  [18,99,100,121].  High 
populations  of  these  cells  have  been  associated  with  chronic  viral  infections  including  human 
immunodeficiency virus (HIV), hepatitis C virus, cytomegalovirus (CMV), and human parvovirus 




with  subclinical  carotid  artery  disease  in  HIV‐infected  women  [99].  Older  CMV  seropositive 
individuals, who had higher number of CD8+CD28−  cells,  responded poorly  to vaccines and had 
early mortality compared to aged‐matched CMV seronegative counterparts [19]. 
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activated CD8+ ll t CD28− T cells exhibit
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CD8+ − T cells are al o shown to be imm nosuppressive and function as regulatory
T cells [122–125]. For example, CD8+CD28− T ells directly inhibit Ag-presenting function of
DCs by inducing inhibitory receptors, such as imm noglobulin like transcript 3 (ILT3) and ILT4,
which leads DCs to be immune tolerant than immunogenic [12 ,126]. Such tolerogenic DCs anergize
alloreactive CD4+ T ce ls and convert the into regulatory T ce ls, which in turn, continue the
immunosuppres ive cascade by tolerizing other DCs and amplify T cell immunosenescenc [126,127].
In vivo, CD8+CD28− T cells have been directly correlate wi h the suppr ssion of antigen-sp cific T cell
responses in patients with plasma cell dyscrasia [123]. Therefore, their h racteristics and functions in
immunity range from reduced antigen-specific killing to enhanced cytotoxic abilities a d from crossing
innate immunity fu ction to promoting immune regulation.
7. CD8+ − T cells in Pathologic Cond tions
CD8+ − T cells play a significant role in patho ogical conditions [18,99,100,121].
High populations of these cells hav been associated with chronic viral infections including human
immunodeficie c vir ( I l ir s ( ), and hu an parvovirus
B19 [99]. Shorten d telomeres, reduced IL-2 production, and increased IL-6 production were observ d
in th se cells [19]. The loss of CD28 als serves s a prognostic indicat r for viral infection. For ins ance,
increased fr quency of CD8+CD28− T cells in the early stag of HIV infection corr lates with f ster
progression to AIDS [99]. Additionally, higher levels of CD8+CD28− T cells are associated with
subclinical carotid artery disease in HIV-infected women [99]. Older CMV seropositive individuals,
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who had higher number of CD8+CD28− cells, responded poorly to vaccines and had early mortality
compared to aged-matched CMV seronegative counterparts [19].
A heterogeneous role was reported for CD8+CD28− T cells in autoimmune diseases [99,108].
Senescent T cell population is increased in patients with Grave’s disease and ankylosing spondylitis
and these cells’ cytotoxicity contributes to autoimmune response [128,129]. In rheumatoid arthritis
patients, clinical response to abatacept, a CD80/86-CD28 T cell co-stimulation modulator, is associated
with a concomitant decrease in CD8+CD28− T cells, suggesting prognostic value for this phenotype [56].
In contrast, patients with systemic lupus erythematosus were found to have reduced CD8+CD28−
T cells [130]. Similarly, in a mice model for multiple sclerosis, adoptive transfer of CD8+CD28−
regulatory T cells have been shown to prevent autoimmune encephalomyelitis [131]. Though treated as
a single phenotype, CD8+CD28− T cells represent a heterogeneous group that has differential activities in
different pathologic conditions. In solid organ transplant recipients, CD8+CD28− T cells have been found
to undergo oligoclonal expansion and play a suppressive role and promote allograft tolerance [108,132].
Elevated CD8+CD28− T cell population in liver transplant patients are associated with better graft
function and reduced rejection rates [133] and contribute to reducing immunosuppressant dosage [124].
In addition, the presence of CD8+CD28− T cells is associated with decreased CD80/86 expression and
increased inhibitory receptor (ILT3, ILT4) in circulating APCs, implying an immunosuppressive role of
this subset [126,133].
8. CD8+CD28− T cells and Cancer
The cycle of anti-tumor immunity starts with the presentation of cancer antigens released from
cancer cell turnover. Resident tissue DCs or lymph nodes residing DCs capture cancer antigens and
present the antigens in the form of peptide-MHC I complex to activate naïve CD8+ T cells. Activated
effector CD8+ T cells travel through blood and lymphatic to reach tumor beds where they execute
cancer-specific killing. This leads to further endogenous antigen release and DC activation, thereby
closing the cycle for anti-tumor immune response [1,28].
The presence of lymphoid aggregates is linked with improved responses to cancer therapies such
as standard cytotoxic therapies, vaccine-based treatments, or immune checkpoint blockades. [5,134]
Immunologically ‘hot’ tumors, such as melanomas and lung cancers, are thus more amenable to
control than ‘cold’ tumors, i.e., tumors with diminished T cell infiltrates, such as GBM. [135,136]
This drives modern cancer therapy to investigate how to redirect the TME to attract the right types of
immune infiltrates.
Effector arm insufficiency, especially CD8+ T cell dysfunction, is a hallmark of inadequate
anti-tumor immune response [16]. Four forms of T cell dysfunction—tolerance, anergy, exhaustion,
and senescence—have all been reported in cancer microenvironment [17,35,137]. Immune tolerance
is a physiological process where the body eliminates self-reacting T cells. Tumor cells, such as GBM,
can mimic peripheral tolerance and facilities FasL-mediated deletion of T cells [17]. Tolerance can
be enforced by TGF-β and IL-10 secreted by Tregs that are recruited in the TME as well as cancer
cells. [17,138,139]. T cell anergy is a T cell hypo-responsive state with low IL-2 production and poor
proliferative capacity [17]. It results from the lack of co-stimulation of TCRs through CD28. This is due
to the competitive binding of CTLA-4 expressed on Tregs to CD80 and CD86 on the APCs [14,17,139].
Anergic T cells display very little to no effector function, but expression on inhibitory markers is
unclear [15]. T cell exhaustion occurs after excessive and continuous stimulation of the TCR and
inflammatory cytokines like IFNα/β. Exhausted T cells have diminished proliferative capacity and
have poor cytokine production and effector function. However, they express high levels of inhibitory
receptors, or immune checkpoints, such as PD-1, CTLA-4, TIM3, LAG3, etc. [15,140]. The degree of
T cell exhaustion can vary with tumor types as well. It is more severe in GBM compared to other
cancers such as breast, lung, and melanoma [137]. T cell senescence can be distinguished from anergy
and exhaustion in their origins and their surface receptors. For example, senescent T cells express
fewer CD28 but more NK receptors, whereas exhausted or anergic T cells express more inhibitory
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receptors such as PD-1 and CTLA-1 (Figure 4). While anergic and exhausted T cells are hyporesponsive
and hypofunctional, senescent T cells were considered metabolically active in their physiological or
pathological environment despite being in cell cycle arrest (Figure 3). Though both T cell anergy and
T cell exhaustion in natural occurrence are considered reversible, T cell senescence was considered
irreversible until recently [14].
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Figure 4. The many facets of C8+ T cell dysfunction. In comparison to activated effector T cells,
T cell anergy, exhaustion, and senescence can be distinguished by their unique expression or lack of
expression of surface receptors as well as different levels of intracellular cytokines, such as IL-2.
Targeting dysfunctional effector T cells has revolutionized the paradigm of tumor immunotherapy
and immune checkpoint inhibitors set a paramount example [141]. Utilizing tumor dysregulation
of immune checkpoint expression in exhausted dysfunctional T cells, immune checkpoint inhibitors
were developed to promote protumor immune landscape [141]. Ipilimumab, CTLA-4 inhibitor, the
first immune checkpoint inhibitor approved by FDA, was used to treat patients with advanced
melanoma and has demonstrated improved survival when given with gp100 melanoma vaccine [142].
PD-1 inhibitors, pembrolizumab and nivolumab, and PD-L1 inhibitors, atezolizumab, durvalumab, and
avelumab soon followed showing promising results. Pembrolizumab and nivolumab demonstrated
40–45% objective response rate in melanoma and non-small cell lung cancer [143]. In urothelial
bladder cancer, use of PD-1/PD-L1 inhibitors showed overall response rate between 13% and 24% [144].
With metastatic brain disease, the combination of ipilimumab and nivolumab showed 56% intracranial
response with 19% complete response from metastatic melanoma, and pembrolizumab have been
shown to demonstrate intracranial activity against melanoma and NSCLC metastasis [145]. Continued
investigation of the safety and efficacy of these novel immunomodulating drugs are ongoing in various
malignancies [146]. However, it has been reported that the presence of functionally aberrant senescent
T cells with loss of CD27 and CD28 and gained expression of CD57 cells was associated with resistance
Int. J. Mol. Sci. 2019, 20, 2810 10 of 22
to checkpoint inhibitor blockade [8]. Therefore, senescent T cell phenotypes are possible predictive
biomarkers for clinical response to checkpoint inhibitor therapy and potential targets to improve
checkpoint inhibitor efficacy.
Increased CD8+CD28− senescent populations displaying heterogeneous roles have been observed
in multiple solid and hematogenous tumors [24]. This immunosuppressive phenotype was initially
observed in patients with plasma cell dyscrasia, where increased number of CD8+CD28− T cells was
present in the bone marrow (i.e., TME) and the amount directly correlated with the suppression of
antigen-specific T cell response [123]. Similarly, in patients with lung cancer, the CD8+CD28− T cells
express elevated Foxp3 and have been shown to play an immunoregulatory role [147]. High levels
of CD8+CD28− T cells were found in patients with advanced stages of non-small-cell lung cancer.
Their numbers declined with resection of the tumor, and the decreased level of CD8+CD28− T cells
correlates with favorable prognosis in tumor management [148]. In contrast, the CD8+CD28− T cell
populations in melanoma patients express perforin, where they contribute to anti-tumor immune
response [149].
CD8+CD28- T cell senescence is triggered by a variety of biological processes including telomere
damage, Treg cells and tumor-associated stresses [150]. Naturally occurring CD4+CD25hiFoxp3+
Treg (nTreg) and tumor-derived γδ Treg cells can induce responder T cell senescence as an
immunosuppressive mechanism [127,151]. Senescent T cells induced by Treg cells have phenotypic
changes, including expression of SA-β-Gal, downregulation of co-stimulatory molecules CD27
and CD28, and promotion of cell cycle and growth arrest in G0/G1 phase [127,151]. Importantly,
CD8+CD28− senescent T cells induced by Treg cells have potent regulatory activities [150] and deepen
immunosuppression in TME [152]. Therefore, CD8+CD28− senescent T cells are important mediators
and amplifiers of immunosuppression mediated by Treg cells. The blockage of Treg-induced senescence
in responder immune cells is critical in controlling tumor immunosuppression and restoring effector
T cell function.
One of the mechanisms for Treg-induced CD8+ T cell immunosenescence is mediated by nuclear
kinase ataxia-telangiectasia mutated protein (ATM)-associated DNA damage in responder T cells
triggered by glucose competition [150]. MAP ERK1/2 and p38 signaling functionally cooperate with
transcription factors STAT1/STAT3 to control Treg-induced senescence in responder T cells [150].
Utilizing these mechanisms, Treg-induced T cell senescence was successfully prevented by inhibiting
the DNA damage response and/or STAT signaling in a recent in vivo mice study [150]. Another
study has shown that senescent T cells are in fact able to regain function by inhibiting the p38
MAPK pathway [153]. Furthermore, human Toll-like receptor 8 (TLR8) signaling can directly target
multiple types of tumors and prevent tumor-induced cell senescence through modulation of levels of
endogenous secondary messenger cAMP in tumor cells [154].
9. CD8+CD28− T cells and Glioblastoma
Despite being isolated in the intracranial compartment by the blood brain barrier, GBM,
the most common and aggressive primary brain tumor in adults, demonstrates a remarkable
level of immunosuppression [155]. Current standard of care for patients with GBM includes
surgery, temozolomide chemotherapy, radiotherapy, and corticosteroids, all of which have potent
immunosuppressive effects. Tumor cells express surface ligands such as PD-L1 and CD95 (Fas/apoptosis
antigen 1) that can lead to T cell suppression via apoptosis and immunosuppressive cytokines like
TGF-β, IL-10, and other tolerance factors [139]. Tumor-associate macrophages, modified neutrophils,
and Foxp3+ Tregs, are also recruited by the tumor to promote its progression [156–158].
T cell dysfunctions including tolerance, anergy, and exhaustion have also been well documented
in GBM [14,17]. However, despite of promise of checkpoint inhibitors in the treatment of several solid
tumors, their therapeutic efficacy in GBM remains to be validated. Phase III clinical trial Checkmate
143 reported that PD-1 monoclonal antibody (nivolumab) monotherapy failed to demonstrate survival
benefits compared to bevacizumab in recurrent GBM patients who were previously treated with
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chemotherapy and radiotherapy [17,69,155]. Ongoing clinical trials are investigating the tolerability
and drug toxicity in combination treatment and in patients with newly diagnosed GBM patients as
well as recurrent GBM patients. The muted response to immune activators seen thus far highlights to
the need for novel strategies to boost immunity to GBM.
The role of T cell senescence in GBM has been reported but is yet to be fully elucidated.
The presence of circulating senescent CD4+CD28−CD57+ T cells was correlated with poor prognosis in
GBM patients [159]. CD8+CD28−Foxp3+ T cells, which have been found in other cancers to cause APC
dysfunction [160], were also identified in TME from patients with GBM [161]. The APCs isolated from
these patients displayed dysfunctional phenotype associated with high levels of ILT2, ILT3, and ILT4
and low levels of CD40, CD80, and CD86 [162]. It is speculated that CD8+CD28− T cells help sculpt an
immunosuppressive environment in a similar fashion in GBM.
The potential pro-tumoral effect of CD8+CD28− cells can also be inferred from worse prognosis
observed in older GBM patients [163]. Since CD8+CD28− cells are derived from the general population of
immature CD8+CD28+ T cells originating from the thymus [99], the production of immature CD8+CD28+
decreases as thymic involution occurs through aging, but also with cancer [164]. This decrease in
immature CD8+CD28+ cells due to thymic senescence has also been associated with poor outcome in
GMB patients [17].
10. Implications of CD8+CD28− T Cells for the Future of Immunotherapy
Since success of immunotherapy largely relies on addressing effector arm dysfunction, as evident
from the success of checkpoint inhibitors, future investigations into new treatment methods should
explore strategies to deplete or inhibit regulatory CD8+CD28− T cells and reverse T cell senescence
as an adjuvant for more effective immunotherapy. There are four main approaches to rejuvenate T
cell pools (1) replacement of senescent cells, (2) reprogramming of the senescent cells to be functional,
(3) adoptive transfer of proficient T cells, and (4) restoration of naïve T cell pool [165].
Replacement strategies include selectively removing senescent cells from the circulation and then
subsequent expansion of memory and effector T cells. Removal of senescent cells is of particular
importance, not only due to their own dysfunction but also due to their ability to and spreads senescence
in bystander cells [166]. A possible approach for their removal is to promote selective apoptosis in
senescent T cells. In a recent study, an engineered peptide that interferes with FOXO4/p53 interaction
induced p53-mediated intrinsic apoptosis in senescent fibroblasts and neutralized doxorubicin-induced
chemotoxicity in vivo [167]. Whether this also can be used in inducing apoptosis of senescent T cell
remains to be investigated. Targeting commonly known senescent cell anti-apoptotic pathways such
as Bcl-2 and ephrins in senescent T cells is also warranted [168]. Homeostatic expansion in the form
of autologous stem cell transplantation has been used to reconstitute functional naïve, memory, and
affect T cell pools in both autoimmune diseases and hematologic malignancies [169,170]. More recently,
senolytic treatment of amyloid-beta (Aβ) peptide -associated senescent oligodendrocyte progenitor
cell in mice with Alzheimer’s disease showed successful selective removal of senescent cells from the
plaque, reduced neuroinflammation, lessened Aβ load, and ameliorated cognitive deficits [171]. This is
of particular interest as a successful application of senolytic therapy in the CNS pathology, such as
GBM. CD8+CD28− cells replacement strategies are still in early phases of development, however their
successful implementation has the potential to complement the current paradigm of immunotherapies.
Re-programming involves differentiating T cells away from dysfunctional states by enhancing
telomerase activity to extend cellular lifespan and preclude replicative senescence [172]. For example,
restoring CD28 expression slows replicative senescence in human T cells through increased telomerase
activity to increase proliferative potential [173]. Additionally, pharmacological inhibition of SRC
homology 2 domain-containing phosphatase-1 (SHP-1), a key regulator of T cell signal transduction
machinery, improved TCR/CD28 signaling and successfully improve T cell functions in elderly
donors [174]. Aptamers, short, single-stranded DNA or RNA molecules, have been engineered to
target immune costimulatory receptors (CD28, OX40 and 4-1BB) and have shown to improve T cell
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activation and induce antitumor response. Aptamers have the benefits of being chemically synthesized,
versatility of targeting motifs, high penetration rate, and ease of neutralization [75]. Re-programming
of T cells present the most promising avenue for anti-CD8+CD28− therapy with wide selection of
potential targets and treatment mechanisms.
Adoptive transfer is to bypass the co-stimulation requirement to re-differentiate pluripotent stem
cells into naïve and cytotoxic T cells to fight malignancy [175]. The development of T cell adoptive
immunotherapy using the third generation of CAR technology by incorporating the intracellular
costimulatory domains to bypass the requirement for CD28 activation is underway. The third generation
CARs T cells were investigated in hematological malignancies and xenograft model of solid tumors
and have shown preclinical success [176–180]. While other types of immunotherapy can cause systemic
side effects, antigen specificity of CAR therapy limits the adverse effect of immunotherapy to its targets,
and they are reversible when the target cell is eliminated, or the engraftment of the CAR T cells is
terminated [181]. However, its high specificity can be a weakness in heterogeneous tumors with
high mutational profiles since CAR therapy can select for cells negative for the targeted antigen [155].
Such was the case for IL-13Rα2 CAR therapy for GBM where recurrence occurred 7.5 months after
treatment despite shrinking all lesions by 77–100% [155].
Finally, restoring and maintaining the thymic environment reverse effects of thymic involution.
Using bioengineered thymus organoids with the help of growth-promoting factors and cytokines
such as IL-21, it has been shown that significant immune restorative function and rejuvenation of the
peripheral T cell pools were achieved in murine models [182]. Unfortunately, current understanding of
thymic restoration is not complete enough for clinical implementation, and there are still unanswered
questions regarding its feasibility in establishing functional naïve T cell production [183,184]. The safe
removal of senescent CD8+ T cells and restoration or differential induction of functional CD8+
cytotoxic T cells would add a promising mechanism to defend host against cancer invasion and fight
immunotolerance of malignancy.
There is theoretical concern that reversing the growth arrest by selective blockage of senescent
T cells carries a risk of malignancy, which is less of a concern for targeting functionally exhausted
T cells [185]. Nevertheless, one may argue that increased theoretical lifetime risk of malignancy is
outweighed by the potential immediate benefit of extending the life expectancy, even by a few months
to years, in the battle against aggressive cancers, such as GBM with a median overall survival of only
20.6 months. Furthermore, the benefits of targeting both immunosenescence and exhaustion may be
more evident with reduced dose requirement for each, thereby reducing risks of drug-associated adverse
events. Potential synergistic efficacy to boost immunity against cancer may also be implemented as
already seen with GITR stimulation/PD-1 blockade and CTLA-4/ICOS stimulation [74,80,81].
11. Conclusions
In summary, functional, tumor specific CD8+ cytotoxic T cells drive the adaptive immune response
to cancer and are the primary endpoint to most immunotherapies. However, the promise of current
cancer immunotherapy has been limited by marked immunosuppression in the TME defined by CD8+
T cell dysfunction, especially in immune ‘cold’ cancers, such as GBM. Among the many facets of
CD8+ T cell dysfunction, including tolerance, anergy, and exhaustion, CD8+ T cell senescence, as
represented by the CD8+CD28− population, is an emerging field and their presence has been described
in many cancers. CD8+CD28− T cells contribute to tumor immunosuppression and resistance to
immunotherapy. Further characterization and investigation into this subset of CD8+ T cells will
provide novel targets for effective immunotherapy and successful cancer control.
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